Research Compound Overview

SS-31 (Elamipretide): The Mitochondrial Peptide That Earned FDA Approval

Last updated: April 16, 2026 · First FDA-approved mitochondrial peptide drug

On September 19, 2025, the U.S. Food and Drug Administration approved elamipretide — known in the research literature as SS-31 — for the treatment of Barth syndrome, a rare genetic disorder of cardiolipin metabolism. The approval was narrow in scope, tied to a single rare disease, but its significance for the broader mitochondrial research field is difficult to overstate. SS-31 is the first peptide ever approved by the FDA that acts directly at the inner mitochondrial membrane. It validates, at the regulatory level, the premise that targeting mitochondrial lipid architecture is a tractable pharmacological strategy.

This article reviews the mechanism of SS-31, the published research establishing how it binds and stabilizes cardiolipin, the Barth syndrome clinical program that led to approval, and the compound's place in the broader mitochondrial peptide research landscape alongside MOTS-c and NAD+ precursors.

Compound Profile

Why Cardiolipin Matters

Cardiolipin is a structurally unique phospholipid: it has four acyl chains instead of the usual two, giving it a conical shape that concentrates preferentially at the sites of high curvature in the inner mitochondrial membrane. Cardiolipin is found almost exclusively at this one location in the cell, where it plays several indispensable roles. It organizes the electron transport chain into functional supercomplexes. It provides the structural scaffold for cristae folding (the pleated inner membrane topology that dramatically expands mitochondrial surface area). It interacts directly with cytochrome c, ATP synthase, and the ADP / ATP translocator. Without intact cardiolipin, none of the central machinery of oxidative phosphorylation functions correctly.

Cardiolipin is also vulnerable. The unsaturated fatty acid chains that give it its distinctive shape are exactly the chemical groups most susceptible to oxidation by reactive oxygen species generated at the electron transport chain. Oxidized cardiolipin is both functionally impaired and pro-apoptotic: it releases cytochrome c from the inner membrane, which is one of the initiating events in intrinsic apoptosis. Cardiolipin peroxidation is therefore mechanistically implicated in a broad range of research areas including ischemia-reperfusion injury, heart failure, age-related muscle decline, and the neurodegenerative diseases.

How SS-31 Works: A Lipid-Targeted Peptide

The binding mechanism

SS-31 is a short cationic tetrapeptide engineered at Cornell by the laboratory of Hazel Szeto. The molecule carries a net positive charge at physiological pH and is structurally designed to partition preferentially into mitochondria — not via an active transporter, but through the large electrochemical gradient maintained across the inner mitochondrial membrane. Once inside the mitochondrion, SS-31 binds selectively to cardiolipin. Published biophysical work has characterized this binding in detail: the peptide associates with cardiolipin through a combination of electrostatic attraction to the anionic headgroup and hydrophobic interaction with the acyl chains.

The functional consequence of this binding is mechanical and chemical stabilization of the inner mitochondrial membrane. SS-31 binding slows cardiolipin peroxidation, preserves the supercomplex organization of the electron transport chain, and appears to protect cristae architecture under oxidative stress. Unlike conventional antioxidants, which scavenge reactive oxygen species already released, SS-31 acts structurally — it keeps the machinery that produces ROS operating efficiently enough that less ROS is generated in the first place.

Foundational mechanistic work

The characterization of SS-31's cardiolipin binding and its functional consequences on mitochondrial energetics was established in a series of papers from the Szeto laboratory and collaborators. The mechanism review published in British Journal of Pharmacology remains the most comprehensive single reference on the pharmacology of mitochondria-targeted tetrapeptides.

The Barth Syndrome Clinical Program

Why Barth syndrome was the approval path

Barth syndrome is a rare X-linked disorder caused by mutations in the TAZ gene, which encodes the enzyme tafazzin. Tafazzin is required for the remodeling step in cardiolipin biosynthesis that produces the mature, tetralinoleoyl form of the lipid. Without functional tafazzin, cells accumulate abnormal monolysocardiolipin and produce an inner mitochondrial membrane with disordered structure and impaired function. Clinically, Barth syndrome presents in early childhood with cardiomyopathy, skeletal myopathy, and neutropenia.

From a pharmacological standpoint, Barth syndrome is a uniquely clean proof-of-concept disease for SS-31: it is defined entirely by a cardiolipin defect, which means any agent that can stabilize or functionally compensate at the cardiolipin level has a well-defined mechanistic rationale. The TAZPOWER trial was designed around functional endpoints relevant to this population, and the regulatory path leveraged the Rare Pediatric Disease program.

The approval data

The FDA's approval of elamipretide for Barth syndrome was supported by the TAZPOWER program and subsequent open-label extension data. The published TAZPOWER results describe functional endpoints including muscle strength and cardiac measures over extended treatment periods, with a safety profile consistent with prior elamipretide studies. The approval in September 2025 marked the first regulatory endorsement of a peptide that acts directly at the inner mitochondrial membrane.

Beyond Barth: Broader Mitochondrial Research

Heart failure

SS-31 has been investigated in multiple heart failure trials on the rationale that cardiolipin peroxidation is implicated in the myocardial bioenergetic dysfunction that defines heart failure with both preserved and reduced ejection fraction. The Phase 2 PROGRESS-HF program and subsequent studies have produced mixed but mechanistically informative results, with particular interest in specific patient subpopulations whose mitochondrial dysfunction profile matches SS-31's mechanism. The heart failure dataset is among the largest single bodies of elamipretide research and is referenced extensively in mitochondrial pharmacology literature.

Primary mitochondrial myopathy

The MMPOWER series of trials examined elamipretide in primary mitochondrial myopathy, a group of genetic disorders of oxidative phosphorylation. The endpoints focused on exercise tolerance and muscle function. The published data from MMPOWER-3 informed subsequent development decisions and provided one of the clearer demonstrations of the compound's muscle bioenergetic effects in a pure mitochondrial-disease population.

Age-related macular degeneration and ophthalmic research

Mitochondrial dysfunction in retinal pigment epithelium is implicated in dry AMD pathophysiology. The ReCLAIM-2 program examined topical elamipretide in this indication, with endpoints focused on geographic atrophy progression and visual function. This line of research continues within the Stealth development program and represents a substantial additional dataset for the compound.

Aging research generally

Cardiolipin composition and peroxidation change with age across multiple tissues, and the hypothesis that cardiolipin-targeted interventions could modulate mitochondrial aging has been examined in preclinical models from several laboratories. This body of research is explicitly preclinical and sits at the mechanistic level; it does not support human-use claims about aging. Researchers interested in the aging biology context should consult the published work on mitochondrial membrane lipidomics and age-related cristae remodeling for the primary literature foundation.

SS-31 in the Mitochondrial Research Landscape

Three distinct classes of mitochondrial research compounds receive most of the attention in the peptide and longevity literature. Each acts through a different mechanism and addresses a different aspect of mitochondrial biology.

Substrate-based: NAD+ precursors (NR, NMN)

NAD+ precursors work upstream of the mitochondrion by raising cellular NAD+ pools. NAD+ is a cofactor for hundreds of enzymes, most notably the sirtuins, and its level declines with age across multiple tissues. Supplementation with nicotinamide riboside or nicotinamide mononucleotide restores NAD+ availability and, in preclinical models, influences sirtuin-mediated processes. NAD+ precursors act at the metabolic and transcriptional level; they do not directly alter mitochondrial membrane architecture. For the full treatment of this pathway see our NAD+ and sirtuin research article.

Signaling-based: MOTS-c

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial 12S rRNA gene. It is one of the so-called mitochondrially-derived peptides and acts as a signaling molecule that influences metabolic homeostasis, particularly in muscle tissue, through AMPK-related pathways. MOTS-c is a regulatory peptide — it adjusts the metabolic program of the cell rather than directly protecting mitochondrial hardware. For detail on MOTS-c mechanism see our MOTS-c research article.

Architecture-based: SS-31 (elamipretide)

SS-31 is the only member of this short list that acts on the physical lipid architecture of the inner mitochondrial membrane itself. It binds cardiolipin, stabilizes supercomplex organization, and preserves cristae structure under conditions that would otherwise produce disorganization. It is mechanistically distinct from both substrate-based and signaling-based approaches. This architectural mode of action is part of what makes the FDA approval in Barth syndrome conceptually important: it is the first regulatory endorsement of targeting mitochondrial lipid architecture as a therapeutic strategy.

These three approaches are not mutually exclusive from a research standpoint. The cell's mitochondria respond to signaling inputs (MOTS-c), metabolic substrate availability (NAD+), and physical membrane integrity (SS-31), and each can be examined independently in research models.

Research Handling and Experimental Considerations

SS-31 is typically supplied as a lyophilized powder and reconstituted in bacteriostatic water or saline for in vitro research use. The peptide is relatively stable compared with larger peptides but should be stored cold and protected from repeated freeze-thaw cycles. Researchers working with SS-31 in mitochondrial preparations should be aware that the compound's mitochondrial uptake depends on intact membrane potential; experiments involving uncouplers or depolarized mitochondria will alter the pharmacology of the compound.

Standard research controls for SS-31 work include scrambled peptide controls (a same-composition, non-cardiolipin-binding sequence) and cardiolipin-deficient preparations where feasible. Cardiolipin content can be assessed by mass spectrometry-based lipidomics, which is the reference method in current mitochondrial research.

Research Limitations

Although SS-31 has an extensive published literature base, several aspects of its pharmacology remain areas of active investigation. The precise stoichiometry of cardiolipin binding under physiological conditions, the compound's behavior at the cristae-junction level, and its pharmacology in tissues with lower baseline mitochondrial membrane potential are all subjects of ongoing work. The FDA approval is specific to Barth syndrome and is built on that specific disease dataset; extrapolation to other indications should reference the published data from those specific research programs rather than assuming general-purpose mitochondrial effects.

Researchers using SS-31 in experimental models should consult the primary biophysical and clinical literature to understand the conditions under which observed effects have been documented, and should design appropriate controls rather than relying on the compound as a general "mitochondrial enhancer."